1. Durable ventricular assist device in Spain (2007-2020). First report of the REGALAD registry
- Author
-
Manuel Gómez-Bueno, Enrique Pérez de la Sota, Alberto Forteza Gil, Daniel Ortiz-Berbel, Javier Castrodeza, María Dolores García-Cosío Carmena, Eduardo Barge-Caballero, Diego Rangel Sousa, Beatriz Díaz Molina, Rebeca Manrique Antón, Luis Almenar-Bonet, Aitor Uribarri González, Alfredo Barrio-Rodríguez, María Ángeles Castel Lavilla, Laura López-López, David Dobarro Pérez, Francisco Pastor Pérez, Virginia Burgos-Palacios, Jesús Álvarez-García, José Manuel Garrido-Jiménez, Óscar González-Fernández, Pau Codina, Amador López-Granados, Andrés Grau-Sepulveda, and José González-Costello
- Subjects
General Medicine - Abstract
This report presents the clinical characteristics, outcomes and complications of all consecutive patients implanted with a long-term mechanical circulatory support device in Spain between 2007 and 2020.Analysis of the Spanish Registry of durable ventricular assist devices (REGALAD) including data form Spanish centers with a mechanical circulatory support program.During the study period, 263 ventricular assist devices were implanted in 22 hospitals. The implanted device was an isolated continuous-flow left ventricular assist device in 182 patients (69%), a pulsatile-flow device (58 isolated left ventricular and 21 biventricular) in 79 (30%), and a total artificial heart in 2 patients (1%). The strategy of the implant was as bridge to heart transplant in 78 patients (30%), bridge to candidacy in 110 (42%), bridge to recovery in 3 (1%) and destination therapy in 72 patients (27%). Overall survival at 6, 12 and 24 months was 79%, 74% and 69%, respectively, and was better in continuous-flow left ventricular assist devices (84%, 80%, and 75%). The main adverse events related to this therapy were infections (37% of patients), bleeding (35%), neurological (29%), and device malfunction (17%).Durable ventricular assist devices have emerged in Spain in the last few years as a useful therapy for patients with advanced heart failure. As in other international registries, the current trend is to use continuous-flow intracorporeal left ventricular devices, which are associated with better results. Adverse events continue to be frequent and severe.
- Published
- 2022